Northwest Biotherapeutics Inc (QB) (NWBO) Cotización

Lol, a judge would not be waiting for approval or not of a company before rendering his/her/zer/their etc... judgment.

The worrying part is this:

Since KG is now (always been, deep state establishment) "an ennemy" of Donald Trump, KG now falls into "allie" of the democrat machine. Lots of Judges, especially NY, DC are extremely corrupt.

Question is will they stop any lawfare agaisnt KG and friends for some favors...
(which is alrdy happening, Musk/Trump stock manipulation).

I kind of wish Trump didnt win the election in a way, since if he didnt win I am pretty sure they would have went after KG... (they do need to sacrifice some people once in a while...).

But since Trump won, KG has now become a stronger asset/friend if we can say. (always have been an allie but more for the Republican establisment/Neo Con etc..., now fully integrated with the Dem, so I dont think theyll prosecute him now)

Will see what happen. No wonder why the decision took so long (waiting for election results, then orders from up above).

I have gone down the alley of dendritic cells and trying to look at alternatives for that time, for a dendritic cell vaccine, that in any way could align with the data in the clinical trial and the results and process covered in the article.

DocLee raises good questions. I have ping-ponged with AI regarding finding alternatives to DCvax-L, better matching the dc vaccine in question used. And have feeded AI with the patents for DCvax-L and the combo patent for DCvax-L and Keytruda (using IL-7).

The Case for DCVax-L Maturity and Evolution

The early phases of DCVax-L development (1996-2008) may have included experimental setups like the one described in the article, with techniques evolving over time:

NWBO might have adapted protocols as they refined the vaccine for broader clinical and regulatory acceptance.
The use of IL-7 in the 2016 study aligns with the 2014 patent on DCVax-L combined with IL-7. Linda Powers’ connection to Revimmune and the collaboration with Cytheris/Reimmune supports the likelihood of experimentation with IL-7-enhanced protocols.

The patent for combining DCVax-L and IL-7, coupled with Linda Powers' involvement with Revimmune and Mac Cheever's presence on NWBO's SAB, strongly suggests a connection between NWBO's work and the trial involving IL-7.

The timeline aligns: experimental work from the late 1990s to early 2000s could represent early iterations of what became DCVax-L.

While there are distinct differences in production methods between the 2016 study and DCVax-L as it is known today, these differences do not entirely rule out the possibility that the study represents an early developmental phase of DCVax-L. The shared use of tumor lysate, GM-CSF, and IL-4, alongside the patent collaboration involving IL-7, strengthens this hypothesis.

The evolution of DCVax-L's process over time suggests that what was tested in the 1996-2008 study could be a precursor or variant of the vaccine

AI itself suggested Vaccell (Japan), HSP-Loaded DC Vaccines and Allogeneic Tumor Lysate-Based DC Vaccines as potential alternatives, and refuting them all, when comparing with the process in said trial paper and article.

AI's argued "GM-CSF, IL-4, Interferon-?, and LPS" could suggest a custom protocol, but ...

Correlation with the Mentioned Study

The study describes GM-CSF, IL-4, Interferon-?, and LPS for dendritic cell maturation, which initially suggests a custom protocol. However:
The focus on autologous cells, tumor lysates, and broad antigen presentation fits DCVax-L's approach.

The described production protocol could reflect a slight variation tailored to the clinical trial but still built upon DCVax-L's patented foundations, particularly regarding antigen preparation and presentation.

I am keen on looking into other dc alternatives that could fit as a better alternative, but the argument, that the study start of said clinical trial, should in any way disqualify DCVax-L is just not true. The trial sponsor or investigator initially submitted the trial's protocol late 1999. Alton Boynton mentioned DCVax-L in an article in 2000. DCVax-L research began in the 1990s.

I will supper dstocks notion, that there are way more pointing to dcvax-l than there are information disqualifying it.

Key Factors Supporting DCVax-L

Broad Antigen Presentation:

DCVax-L's core design is based on broad antigen presentation using whole tumor lysate, which aligns perfectly with the trial description. Very few other DC vaccines emphasize this aspect, especially in 2016.

Autologous Tumor Lysates:

The freeze/thaw preparation of tumor lysate is a hallmark of DCVax-L. This level of standardization was uncommon in custom or experimental protocols of the era.

Dendritic Cell Maturation Process:

While the study describes a slight variation (e.g., GM-CSF, IL-4, Interferon-?, LPS), these differences could reflect specific trial modifications to explore alternative maturation agents or optimize immune responses for that setting.

Patented DCVax-L processes allow flexibility in maturation cocktails, as demonstrated in related patents, making this variation plausible.
Absence of HSP or Narrow Epitope Focus:

No mention of heat-shock proteins (HSP) or specific peptide epitopes rules out vaccines like HSP-loaded DCs or ICT-107, which focused on narrow antigen presentations.

Unique Cryopreservation Difference:

The trial's lack of cryopreservation appears logistical or trial-specific rather than a fundamental process change. DCVax-L is capable of same-day vaccine administration, even though cryopreservation is standard.

Patent Correlation with IL-7:

DCVax-L patents explicitly discuss IL-7 as an adjuvant or immunomodulatory agent to enhance dendritic cell vaccine efficacy. The trial's use of CYT107 (recombinant IL-7) fits this patented approach.

Counterpoints Addressed

Custom Protocol Possibility:

While the described maturation process (GM-CSF, IL-4, Interferon-?, LPS) might initially suggest a custom DC vaccine, the emphasis on broad antigen presentation and tumor lysates aligns poorly with custom vaccine designs, which were often more focused on narrow targets.

Other Candidates:

ICT-107, HSP-loaded DCs, and other experimental platforms fail to match the key elements of the process, including antigen breadth and tumor lysate use.

Remaining Uncertainty (5%)

The small chance of another DC vaccine stems from the possibility of an undisclosed proprietary or experimental platform closely mimicking DCVax-L's process.

However, no evidence of such a platform from that period strongly challenges DCVax-L's precedence.

Read the chain of posts and try to understand the context if you have ability to do so

Amazing that CNBC Fast Money finally covers Naked Short Selling.......

https://x.com/xMarketNews/status/1858941175798907150

I’ll read it. Thanks!

Probably how the market makers are avoiding a short squeeze. Total Bull Shit.

You might also want to stop wasting your time posting. Just saying...

I had not restrictions on how many 10k share blocks I ordered, but I couldn't just buy a bigger block.

Gary 

If there is low volume it’s easy for the market makers to control and lower the price. What a better way to control the volume than slap a restriction on purchasing. We should all complain to the NY Attorney General.

Everyone has 50% chance of getting cancer at certain stage. This year the country has a record of 2m new cancer cases. I suspect the number will keep going up. We can have a sense from 20% increase of Merck's revenue in keytruda each quarter. But the dark forces simply don't want to make this revolutionary treatment available for people on the main street. They have no soul.

>>However, the investigators saw no significant difference in overall survival for patients who received temozolomide and veliparib compared to those who received temozolomide and placebo. The average overall survival was 24.8 months in the placebo group and 28.1 months for the veliparib group.  


https://news.feinberg.northwestern.edu/2024/11/20/combination-therapy-does-not-extend-survival-in-glioblastoma/

dstuck talking about being trapped deep. LOL

Georgebailey - Thx 👍

Posner notified

It will be a trillion dollar company sooner or later. The reason you fail to see it is because you are simply not equipped with sound understanding about the science.

Let me ask you simply questions.
How many DC vaccines can trigger massive t-cell infiltration into cold tumor sites? Let me tell you the answer. There is only one which is owned by NWBO.

Do you know why massive t-cell infiltration can be triggered? Let me tell you the answer again. Dendritic cells trained and primed by NWBO's technology can present hundreds of tumor-associated antigens to immune system. That's why.

Since you are betting against the revolutionary, I suggest you digest the following. Patients with three difficult-to-treat cold tumors were treated with DC vaccines manufactured with NWBO technology and the efficacy was absolutely stunning. Over 30% of metastasized or recurrent cancer patients, mostly children were saved.

See what happened to patient #2 who had cancer metastasized everywhere? After receiving DC vaccine without CYT107, the patient was cancer free for 4.5 years before the paper publication.

See the measurement of biomarker FOXP3? FOXP3 is the one that plays a crucial role in immunosuppression characterized by Treg cells. Here is a piece of homework for you. Go and search which company has FOXP3 inhibitor or inhibitors that can overcome immunosuppression resulted from Treg cells.

It is okay to bet against something only under the condition you have a full understanding about it. Unfortunately, you have no clue about the one you are betting against.

Abstract

Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens that induce high remission rates associated with profound lymphocyte depletion, but ultimately few survive long term. We administered adjuvant immunotherapy to patients with metastatic and recurrent pediatric sarcomas in an effort to improve outcomes.

Experimental Design: Mononuclear cells were collected via apheresis, and tumor lysate was acquired via percutaneous biopsy at enrollment. Participants received standard antineoplastic therapy, followed by autologous lymphocytes, tumor lysate/keyhole limpet hemocyanin–pulsed dendritic cell vaccinations ± recombinant human IL7. Primary outcomes were toxicity and vaccine responses. Secondary outcomes were immune reconstitution, event-free survival, and overall survival (OS).

Results: Forty-three patients enrolled and 29 received immunotherapy. The regimen was well tolerated. Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rhabdomyosarcoma vs. other sarcomas) and response to standard therapy (74% no residual disease vs. 0% residual disease). Five-year intent-to-treat OS of patients with newly diagnosed metastatic Ewing/rhabdomyosarcoma was 77%, higher than previously reported in this population and higher than observed in a similar group treated with an earlier adjuvant immunotherapy regimen (25% 5-year OS). T-cell responses to autologous tumor lysate were identified in 62% of immunotherapy recipients, and survival was higher in those patients (73% 5-year OS with vs. 37% without immune response, P = 0.017). Immune reconstitution, measured by CD4 count recovery, was significantly enhanced in subjects treated with recombinant human IL7.

LP is absolutely eight balls ahead. That's why you and your buddies are trapped deep.

Carry on your little dirty game.

As usual, nothing to see here. Glad i have stopped wasting my time looking!

I suppose that you think people should work for free.

Thanks for your thoughts on tax loss harvesting. I am doing that.

Lol
It's called hanging on to straws 

So Harrington hired a highly sophisticated expert witness, who specializes in uncovering market manipulation schemes worth every penny of his $1,100/hr compensation rate. Very impressive post by the H man on "X."

So many rapid fire empty postings here pushing anything worthwhile so far down the page that nobody gets to reads them.

Side note:

Bigger tweeted a few days after 5/10 saying they’ll halt OTC on the way up, but don’t halt on the way down. Quite the interesting point which should 100% be brought up in the case.

You’d think, but I won’t be that test dummy. This sh** is getting ridiculous.

Today there was a string of twenty-three 1 share trades
https://x.com/smith348572/status/1859336963297509530
Hopefully they're not gearing up to drop the limit to 1

Seems that way. But, I was pretty miffed. 50k shares is under a 15k trade and I was thinking how desperate are these F*.
This is a major red flag for using Fidelity and a major red flag signal by shorts.

Flip I was thinking about doing that on the sell side but decided against.

1 buy of 20k will work the same as 2 buys of 10k on squeeze day, no?

Yes I think they bypass the limitation as non retail traders even if with Fidelity.
Ive been buying in one trade over the fidelity limitation every week since we hit 30 cents….today was the first time I received the message that trading volume would not permit my trade so I broke up the trade and executed.

But shouldn’t they restrict the sale lot size as well? Seems like it only applies to some brokerages and some buyers?

Others are discussing the Fidelity limit on Reddit, but they don't mention which security.
https://www.reddit.com/r/fidelityinvestments/comments/1grxuld/trade_error_314217_the_share_quanitty_is_limited/

‘SEC rule 15c3-5, broker-dealers like Fidelity must implement such controls to prevent potentially disruptive trading.’

This rule has been in place since 2011. Ironic they put this rule into place last Thursday for an OTC stock that trades less than 5% OS and steady decline for 4 years when they happen to be on the brink of major approval.

Didn’t seem to be a factor on 5/10.

Hmm. Shorts have to buy to cover, would they also have limits or just bypass fidelity and other retail brokerages?

RRH happened to me today. There’s a large short position and Fidelity is trying to contain potential damage to shorts- MO.
I am asked every day to loan shares for maybe 6 months.

https://x.com/peter_brit/status/1859104665423516138?t=cyOzyauDAhe2yHUBKGes7w&s=19

You're still wrong from your Green yesterday and I am right that EOD it's going to be RED! Why don't you celebrate with the .66% today! lol

I would recommend sending that info to Posner and NWBO.

It is not a backup ingredient. It is a replacement that should outperform BCG. I just commented on Flip where he used "backup." I am well aware that LP is searching for a replacement due to the shortage. Maybe you need to broaden your vocabulary. Just because you didn't see the word "replacement" doesn't mean you didn't understand the thought I was trying to convey. Don’t be foolish. LP is searching for a replacement due to the shortage, not to outperform BCG. You cult thinks highly of LP to the point that you misunderstood her statement. If LP mentioned about it, it indicates LP already had verifiable data that validated and verified the replacement. You cult always think that LP is ahead of the game where in-fact she was always late. Stop your BS that she already has replacement. It was clearly stated that they're in search of it and now you assumed they already have replacement. You're a clown! Do you know that?

Conspiracy likely. Coincidence, not so much.

NY Attorney General might be interested, and Ms. Posner.

Bigger should also be notified.

looks that way. haven't seen complaints about other brokers besides fidelity. yet.

See my edit.

The response from Fidelity was reported to be 'strange' but they didn'l elaborate.

https://x.com/joeretired41/status/1858551582121443434

https://x.com/joeretired41/status/1857545004245463243

Why the limit? Oh, I see, they can’t pause OTC
Trades, so if they decrease buying speed, sells can still outpace buys if good news hits?

That sounds like suspicious activity.

Gary,

Should we worry that Fidelity will freeze the trade when squeeze is triggered? We know the number of fail-to-deliver shares may be a staggering number. I recall Bright Boy suggested us that we should register shares under our own names.

I saw others posting on twitter the last few days that Fidelity orders for NWBO greater than 20k or so were being rejected, but that smaller orders were accepted.

the judge is waiting

I doubt there is any legal basis for that.

Interesting that you bring this up.  The last 2 days I've been buying through Fidelity, they forced me to put in multiple smaller orders rather than one order with all the shares on one order.  Most were 10k, but some 20k orders were permitted today.

Gary 

Not as a reliable source in the United States. For instance, clinics were recently trying to give Tice BCG in limited doses. you can google it. A Patient on this very message board had trouble getting it to treat his bladder cancer. But, by not expanding production to a new site, Merck increased demand and decreased availability thereby increasing their profit. Wise guys, and not in a good way.🤨

I think shortage usually means it is harder to get so either available quantities are more limited or more expensive or both, but usually means it is still available.